Vericel (NASDAQ:VCEL) Insider Jonathan Siegal Sells 1,500 Shares of Company Stock

Vericel Corporation (NASDAQ:VCEL) insider Jonathan Siegal sold 1,500 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $52.90, for a total value of $79,350.00. Following the transaction, the insider directly owned 1,259 shares of the company’s stock, valued at approximately $66,601.10. This trade represents a 54.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Vericel Stock Performance

Vericel stock traded up $2.84 during midday trading on Friday, reaching $54.62. The company’s stock had a trading volume of 1,612,332 shares, compared to its average volume of 564,100. The firm has a market capitalization of $2.80 billion, a PE ratio of 85.35 and a beta of 1.08. Vericel Corporation has a fifty-two week low of $28.95 and a fifty-two week high of $55.60. The stock’s 50 day simple moving average is $41.01 and its 200 day simple moving average is $38.90.

Vericel (NASDAQ:VCEL) last issued its earnings results on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.21. The company had revenue of $85.37 million during the quarter, compared to analysts’ expectations of $77.95 million. Vericel had a net margin of 7.91% and a return on equity of 6.91%. The firm’s quarterly revenue was up 26.5% compared to the same quarter last year. During the same period last year, the company posted $0.10 earnings per share. Equities analysts predict that Vericel Corporation will post 0.54 earnings per share for the current year.

Institutional Trading of Vericel

Hedge funds have recently added to or reduced their stakes in the business. MCF Advisors LLC lifted its holdings in Vericel by 293.0% in the second quarter. MCF Advisors LLC now owns 782 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 583 shares during the period. Ameritas Advisory Services LLC bought a new stake in shares of Vericel in the 2nd quarter worth $36,000. Allworth Financial LP acquired a new stake in shares of Vericel in the second quarter valued at $60,000. Meeder Asset Management Inc. acquired a new stake in shares of Vericel in the first quarter valued at $61,000. Finally, Integrated Wealth Concepts LLC bought a new position in Vericel during the second quarter valued at about $72,000.

Wall Street Analysts Forecast Growth

VCEL has been the subject of a number of recent research reports. HC Wainwright lifted their price objective on Vericel from $72.00 to $75.00 and gave the stock a “buy” rating in a research report on Friday. Canaccord Genuity Group set a $60.00 price target on shares of Vericel in a report on Thursday, July 30th. TD Cowen boosted their price objective on Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Weiss Ratings reissued a “hold (c)” rating on shares of Vericel in a research report on Thursday, October 29th. Finally, Truist Financial set a $65.00 price target on shares of Vericel in a report on Friday. Four research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $60.80.

Vericel News Roundup

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported Q3 revenue of $85.4 million, up 26.5% year over year and above the $78.0 million consensus. Earnings per share of $0.27 also topped estimates of $0.06, while net income rose 179% to $14.2 million. Vericel Q3 results and guidance
• Positive Sentiment: The company raised its FY2026 revenue outlook to $344 million–$346 million, above analyst expectations of roughly $336 million, and lifted its adjusted EBITDA margin guidance to 28%. The stronger outlook, alongside record MACI sales, helped fuel investor optimism. Vericel shares rise on record revenue and higher outlook
• Positive Sentiment: HC Wainwright raised its price target to $75 from $72 and maintained a Buy rating, signaling continued analyst confidence in the stock’s prospects. HC Wainwright price target update
• Negative Sentiment: Several Vericel directors and insiders disclosed stock sales totaling about 22,000 shares on November 4–5. One insider’s sale reduced their reported stake by 88%, which may be a near-term concern for investors, though insider sales alone do not establish a negative outlook. SEC insider transaction filing

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.